| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 237.14 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Patients with severe thrombocytopenia are presumed to be at increased risk for bleeding, and consequently it has been a standard practice for the past four decades to give allogeneic platelet transfusions to severely thrombocytopenic patients as supportive care. Platelet transfusions may be given either prophylactically to reduce the risk of bleeding, in the absence of clinical hemorrhage (prophylactic transfusions), or to control active bleeding when present (therapeutic transfusions).
Description
Keywords
Alloimmunization Bone Marrow Hemostasis Platelet Refractoriness Platelet Transfusion Stem Cells
Pedagogical Context
Citation
Cardiovasc Hematol Disord Drug Targets. 2017;17(3):180-184. doi: 10.2174/1871529X18666171227152937.
Publisher
Bentham Science Publishers
